Table 2. Intraocular pressure across the treatment groups and time points.

Treatment group	Baseline				6 Weeks				3 Months
	0800 hours	1000 hours	1500 hours	1700 hours	0800 hours	1000 hours	1500 hours	1700 hours	0800 hours	1000 hours	1500 hours	1700 hours
BBFC
N	427	427	427	427	405	402	402	400	385	383	383	383
Mean±SDa	27.0±2.7	25.5±2.9	24.0±3.4	23.7±3.5	20.0±3.9	16.9±3.5	18.6±3.7	16.4±3.5	20.2±4.1	17.0±3.8	18.5±3.8	16.5±3.8
LS mean±SEa	NA	NA	NA	NA	20.6±0.2	17.5±0.2	19.2±0.2	17.0±0.2	20.8±0.2	17.6±0.2	19.1±0.2	17.1±0.2
Brinzolamide
N	453	453	453	453	438	434	434	434	429	426	424	424
Mean±SDa	27.2±2.7	25.7±3.0	24.1±3.4	23.9±3.6	21.3±4.1	19.7±3.8	19.6±3.5	19.2±3.6	21.2±4.2	19.9±3.9	19.9±3.8	19.5±3.8
LS mean±SEa	NA	NA	NA	NA	21.9±0.2	20.4±0.2	20.2±0.2	19.8±0.2	21.8±0.2	20.6±0.2	20.6±0.2	20.2±0.2
Brimonidine
N	448	448	448	448	420	416	412	410	395	393	392	389
Mean±SDa	27.2±2.7	25.6±2.9	24.0±3.3	23.7±3.5	22.2±4.5	18.9±3.8	20.4±4.1	17.8±3.5	22.5±4.3	19.0±3.7	20.6±4.0	18.0±3.8
LS mean±SEa	NA	NA	NA	NA	22.9±0.2	19.5±0.2	21.1±0.2	18.5±0.2	23.2±0.2	19.7±0.2	21.4±0.2	18.8±0.2
P-valueb
BBFC vs brinz	NA	NA	NA	NA	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001
BBFC vs brim	NA	NA	NA	NA	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001

Abbreviations: BBFC, brinzolamide 1%/brimonidine 0.2% fixed combination; brim, brimonidine; brinz, brinzolamide; LS, least squares; NA, not applicable.

Intraocular pressure was analyzed using the intent-to-treat population.

^aMeasured in mm Hg.

^bPairwise t-test based on LS means.